Austin Health

Title
Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica.
Publication Date
2021-01
Author(s)
Owen, Claire E
McMaster, Christopher
Liew, David F L
Leung, Jessica L Y
Scott, Andrew M
Buchanan, Russell R C
Subject
glucocorticoids
lymphocytes
neutrophils
polymyalgia rheumatica
prognosis
Type of document
Journal Article
OrcId
0000-0002-2694-5411
0000-0001-8451-8883
0000-0002-3834-2706
DOI
10.1111/1756-185X.14000
Abstract
Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) correlate with disease activity in several rheumatic diseases; however, their utility in polymyalgia rheumatica (PMR) remains unclear. This study evaluated their relationship with disease activity and glucocorticoid resistance in PMR. Data for disease activity (PMR-AS) and full blood examination was obtained from a prospective observational cohort comprising newly diagnosed, steroid-naïve PMR patients treated with low-dose glucocorticoid therapy. Glucocorticoid resistance was defined as non-response to prednisolone 15 mg/d or initial response followed by flare (PMR-AS ≥ 9.35 or ∆ ≥6.6) upon weaning to 5 mg/d. Univariable Bayesian linear regression analysis of the relationship between PMR-AS (baseline and mean) and NLR and PLR was performed. Predictors of glucocorticoid resistance were identified using a multivariable outcome model, with variables derived from Bayesian model selection. Of the 32 included patients, 16 (50%) fulfilled the primary outcome measure of glucocorticoid resistance. These participants were older, typically female, and had higher baseline C-reactive protein than their glucocorticoid-responsive counterparts. A statistically significant relationship was identified between PMR-AS and both NLR (odds ratio [OR] 28.1; 95% CI 1.6-54.7) and PLR (OR 40.6; 95% CI 10.1-71.4) at baseline, with PLR also found to correlate with disease activity during follow-up (OR 15.6; 95% CI 2.7-28.2). Baseline NLR proved a statistically significant predictor of glucocorticoid-resistant PMR (OR 14.01; 95% CI 1.49-278.06). Baseline NLR can predict glucocorticoid resistance in newly diagnosed PMR patients. Both NLR and PLR may be reliable biomarkers of disease activity in PMR.
Link
Citation
International Journal of Rheumatic Diseases 2021; 24(1): 56-62
Jornal Title
International Journal of Rheumatic Diseases

Files:

NameSizeformatDescriptionLink